SequelSEC

Ensysce Biosciences, Inc. ENSC

Pharmaceutical Preparations · CIK 0001716947 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$5.07M
Fiscal year ended 2025-12-31
Operating income
-$10.24M
Fiscal year ended 2025-12-31
Free cash flow
-$7.93M
Fiscal year ended 2025-12-31

Ensysce Biosciences, Inc. (ENSC) reported revenue of $5.07M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Ensysce Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Ensysce Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$5.07M$5.21M$2.23M$2.52M$3.53M$3.93M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$10.24M-$6.73M-$10.72M-$24.22M-$19.87M-$1.61M
Net incomeUnavailableUnavailableUnavailableUnavailableUnavailable$4.31M
Research & development$10.38M$7.22M$7.59M$19.84M$4.69M$4.39M
Weighted-average diluted sharesshares 2.56Mshares 697.69Kshares 150.94Kshares 179.92Kshares 20.16Mshares 16.51M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable$4.56M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailable$244.49K
Diluted EPS$-3.98$-11.45$-70.40$-139.42$-1.48$0.00
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable$18.71M$1.15M
General & administrative$4.93M$4.72M$5.36M$6.91M$18.71MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Ensysce Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$4.31M$3.50M$1.12M$3.15M$12.26M$194.21K
Total assets$7.45M$5.60M$2.71M$5.89M$16.42M$351.81K
Current assets$7.25M$5.34M$2.29M$5.30M$15.66M$347.88K
Total liabilities$4.57M$2.22M$3.36M$9.91M$24.58M$7.01M
Current liabilities$4.57M$2.21M$3.33M$9.46M$16.48M$7.01M
Total equity incl. NCI$2.88M$3.38M-$651.27K-$4.03M-$8.16M-$6.66M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$52.94K
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.27M$1.36M$1.94M$2.94M$301.10K$1.72M

Cash flow

Ensysce Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$7.81M-$7.50M-$10.78M-$17.89M-$8.24M-$1.25M
Capital expenditures$123.64KUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$123.64KUnavailableUnavailable$4.50KUnavailable$183.40M
Financing cash flow$8.74M$9.88M$8.76M$8.77M$20.31M$1.10M
Net change in cash$808.28K$2.38M-$2.02M-$9.12M$12.07M-$147.32K
Stock-based compensation$177.09K$110.72K$879.16K$1.07M$121.76K$178.68K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable$184.78M
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Ensysce Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$7.93MUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-202.1%-129.2%-480.5%-959.9%-562.7%-41.0%
FCF margin-156.5%UnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue3.5%2.1%39.4%42.5%3.4%4.5%
Current ratio1.59x2.42x0.69x0.56x0.95x0.05x
Revenue YoY growth-2.8%133.6%-11.6%-28.5%-10.2%Unavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue204.8%138.6%340.2%786.1%132.8%111.7%
CapEx / revenue2.4%UnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable5.4%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ENSC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2020-12-31

Operating, investing and financing flows differ from the reported change in cash by 183403653, beyond tolerance 1834036.53.